Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis

Lauren Sahakian,* Rhiannon T. Filippone,* Rhian Stavely, PhD,*,†† Ainsley M. Robinson, PhD,* Xu Sean Yan, PhD,* Raquel Abalo, PhD,‡,§ Rajaraman Eri, PhD,‡ Joel C. Bornstein, PhD,† Mark R. Kelley, PhD,** and Kulmira Nurgali, PhD*††‡‡

Background: Inflammatory bowel disease (IBD) associates with damage to the enteric nervous system (ENS), leading to gastrointestinal (GI) dysfunction. Oxidative stress is important for the pathophysiology of inflammation-induced enteric neuropathy and GI dysfunction. Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a dual functioning protein that is an essential regulator of the cellular response to oxidative stress. In this study, we aimed to determine whether an APE1/Ref-1 redox domain inhibitor, APX3330, alleviates inflammation-induced oxidative stress that leads to enteric neuropathy in the Winnie murine model of spontaneous chronic colitis.

Methods: Winnie mice received APX3330 or vehicle via intraperitoneal injections over 2 weeks and were compared with C57BL/6 controls. In vivo disease activity and GI transit were evaluated. Ex vivo experiments were performed to assess functional parameters of colonic motility, immune cell infiltration, and changes to the ENS.

Results: Targeting APE1/Ref-1 redox activity with APX3330 improved disease severity, reduced immune cell infiltration, restored GI function, and provided neuroprotective effects to the enteric nervous system. Inhibition of APE1/Ref-1 redox signaling leading to reduced mitochondrial superoxide production, oxidative DNA damage, and translocation of high mobility group box 1 protein (HMGB1) was involved in neuroprotective effects of APX3330 in enteric neurons.

Conclusions: This study is the first to investigate inhibition of APE1/Ref-1’s redox activity via APX3330 in an animal model of chronic intestinal inflammation. Inhibition of the redox function of APE1/Ref-1 is a novel strategy that might lead to a possible application of APX3330 for the treatment of IBD.

Key Words: APE1/Ref-1, APX3330, enteric nervous system, chronic intestinal inflammation, IBD, oxidative stress, DNA damage

INTRODUCTION

Inflammatory bowel disease (IBD) is defined by chronic recurrent inflammation of the gastrointestinal (GI) tract, characterized by periods of remission and relapses. It is estimated that more than 5 million people globally suffer from IBD.1 Inflammatory bowel disease encompasses 2 major chronic idiopathic conditions, ulcerative colitis (UC) and Crohn's disease (CD). Ulcerative colitis is confined to the rectum and colon, where it is characterized by mucosal and submucosal ulcerations. In comparison, CD is transmural and displays skip lesions throughout the GI tract, resulting in strictures or fistulas.2 Inflammatory bowel disease is a complex, multifactorial disorder, and the exact cause is ambiguous. Current treatments are limited by their...
inefficacy and toxic side effects. Most present treatments focus on reducing clinical symptoms and do not exploit the pathogenic mechanisms of the disease; therefore, targeting pathophysiological mechanisms including enteric neuropathy may lead to more effective treatments.

The enteric nervous system (ENS) consists of networks of intrinsic neurons embedded in the wall of the GI tract and controls GI functions with little assistance from the central nervous system. Damage to the ENS is associated with GI dysfunction. The ENS has a vital role in GI immunity, as interactions between enteric neurons and immune cells are important in both normal and pathological conditions. Intestinal inflammation-induced ENS damage associates with a compromised GI antioxidant capacity.

Investigating oxidative stress in inflammatory conditions will provide insight into the pathogenesis of IBD and help to develop new therapies. Exposure of enteric neurons to oxidative stress results in disruption of physiological functions. Colon biopsies from IBD patients have shown increased levels of nitric oxide (NO) and oxidative stress–induced DNA damage measured with a specific marker, 8-hydroxydeoxyguanosine (8-OHdG). Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a vital dual functioning protein that regulates the cellular response to oxidative stress and acts as a DNA repair protein. The redox active domain of APE1/Ref-1 regulates cellular stress responses, angiogenesis, inflammation, and proliferation. In contrast, its endonuclease repair domain associates with DNA repair. Multiple inflammatory conditions produce oxidative stress, resulting in altered APE1/Ref-1 responses; without interception by redox activation, cell apoptosis and carcinogenesis are likely. Previous studies have demonstrated increased APE1/Ref-1 redox activity in tissues removed from IBD patients with active inflammation, indicating underlying oxidative stress within the GI tract. In addition, increased expression of APE1/Ref-1 was observed in colon sections from rats with dextran sodium sulfate (DSS)-induced colitis, which has been associated with an enhanced pro-inflammatory response. Thus, APE1/Ref-1 is involved in the pathobiology of GI inflammation. Furthermore, APE1/Ref-1 endonuclease activity protects dorsal root ganglion (DRG) neurons from inflammation and chemotherapy-induced oxidative stress and DNA damage.

In this study, we investigated the APE1/Ref-1 redox domain inhibitor, APX3330, as a potential therapeutic agent for treatment of chronic colitis and inflammation-induced enteric neuropathy using the Winnie murine model of spontaneous chronic colitis. In Winnie mice, spontaneous colitis develops from a primary intestinal epithelial defect conferred by a mutation in the Muc2 mucin gene, leading to intestinal inflammation at 5 to 6 weeks of age and progressing to severe colitis by the age of 12 to 16 weeks. This model closely represents pathophysiological mechanisms and clinical manifestations of human IBD.

METHODS

Animals
Male and female Winnie mice (12 w.o; 20–30 g; n = 24) were obtained from the Victoria University Werribee Animal Facility (Melbourne, Australia). Male and female C57BL/6 mice (12 w.o; 20–30 g; n = 12) were obtained from the Animal Resources Centre (Perth, Australia) and were used as controls. All mice were acclimatized for 3 days before receiving their allocated treatments. All mice were housed at the Western Centre for Health, Research, and Education (Melbourne, Victoria, Australia) in a temperature-controlled environment at 22°C with a 12-hour day/night cycle. All animals had free access to food and water. All experimental procedures in this study were conducted in agreement with the Australian National Health and Medical Research Council (NHMRC) guidelines and under animal ethics AEETH 13/001 and AEC 17/016 approved by Victorian University Animal Experimentation Ethic Committee (AEEC).

Administration of APX3330
Winnie mice were randomly divided into 2 groups: APX3330-treated and sham-treated. Winnie APX3330-treated mice received APX3330 (Kelley Laboratory, Indianapolis, IN, USA) at a dose of 25 mg/kg via daily injections dissolved in cremophor (2%; Sigma-Aldrich): ethanol (2%) in sterile water (96%; 30G needle, max volume 200 µL). The dose of APX3330, route of administration, and vehicle solution were based on previous studies in mice. Mice received the treatment over 2 weeks, twice daily with a 12-hour interval. Winnie sham-treated mice received the vehicle daily injections of cremophor (2%; Sigma-Aldrich): ethanol (2%) in sterile water (96%; 30G needle, max volume 200 µL) according to the same regimen as the treatment group.

Disease Activity
Disease activity in Winnie mice can be characterized by clinical signs including rectal prolapse, diarrhea, changes in colon length, and body weight. Mice were monitored throughout the treatment period for clinical symptoms. Body weights were recorded daily over a 14-day period and expressed as a percentage of change from the body weight at the start of the treatment. Directly after culling on day 15, the whole colon was excised, and the length was measured to assess changes in colon morphology. Fecal water content was assessed by collection of fresh fecal samples at day 14 before culling for ex vivo motility experiments. Fecal samples were
collected by placing each mouse in a separate sterile cage without bedding until the expulsion of the fecal mass. The samples were immediately weighed to record the wet weight then placed in an oven at +60°C for 24 hours. Dry weight was recorded, and the difference between the wet and dry weight (water content) was calculated as a percentage of the wet weight.

**Assessment of Intestinal Inflammation**

Measurement of fecal lipocalin (Lcn)-2 was used as a non-invasive detection of anti-inflammatory efficacy of APX3330 treatment. Fecal samples collected on day 14 from C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice were reconstituted in PBS-0.1% Tween 20 (100 mg/mL) to form a homogenous fecal suspension. This was centrifuged for 10 minutes at 12,000 RPM at 4°C. Lcn-2 levels were estimated in the fecal pellet supernatants using Mouse NGAL ELISA Kit Lcn-2 (Abcam 199083). All samples were run in duplicate for statistical value. A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm, was used to detect Lcn-2 protein (pg/mL) in the fecal pellet supernatant.

**Gastrointestinal Transit**

GI transit was measured via a noninvasive radiological method in C57BL/6 control mice and APX3330-treated and sham-treated Winnie mice after completion of treatment on day 14 as previously described. Briefly, C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice received barium sulfate as contrast (2.5 mg/mL; max-volume of 200 µL; X-OPAQUE-HD) via oral gavage. Sequential x-rays were taken using HiRay Plus Porta610HF x-ray apparatus (JOC Corp, Kanagawa, Japan; 50 kV, 0.3 mAs, exposure time 60 ms) immediately postbarium sulfate administration (0 min) and then every 10 minutes for the first hour, followed by every 20 minutes until expulsion of the first pellet with barium sulphate or a maximum of 4 hours. Images were processed through Fujifilm FCR Capsule XL11 and analyzed on eFilm 4.2.0 software. Parameters of GI transit were measured by time (mins) to determine contrast passing through whole GI tract (whole transit time), stomach to cecum (gastro-cecal transit time; GCTT), cecum retention time, and leaving cecum to anus (colonic transit time; CTT). The C57BL/6 control, APX3330-treated, and sham-treated Winnie mice were culled on the following day (day 15), and tissues were collected for ex-vivo studies.

**Organ Bath Experiments for Isolated Colonic Motility**

Whole colons were removed from C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice in oxygenated physiological saline, and ex vivo organ-bath colonic motility experiments were performed as described previously. Briefly, colons were positioned horizontally and cannulated at the oral and anal ends in an organ bath superfused with Kreb’s solution (composition in mM: NaCl 118, KCl 4.6, CaCl2 3.5, MgSO4 1.2, NaH2PO4 1, NaHCO3 25 and d-Glucose 11; bubbled with 95% O2 and 5% CO2) while maintained at a constant temperature of 37°C. The oral cannula was connected to a reservoir containing Kreb’s solution that was adjusted to maintain intraluminal pressure (0 to +2 cm H2O). The anal end was coupled to an outflow tube with a maximum backpressure of 2 cm H2O. Colonic contractile activity was recorded by a video camera positioned above the organ bath. Tissues were left to equilibrate at constant intraluminal pressure for 30 minutes followed by 2 sequential 20-minute video recordings of colonic contractile activity. Videos were transposed into spatiotemporal maps with Scribble v2.0 software and were analyzed using MATLAB v2017a software to assess parameters of colonic motility.

**Tissue Collections**

Distal colon tissues were harvested in oxygenated physiological saline, flushed clear of fecal content, and cut along the mesenteric border. Tissues were pinned down with the mucosal side up in a Sylgard-lined Petri dish and fixed with Zamboni’s fixative (2% formaldehyde containing 0.2% picric acid) overnight at 4°C. The fixative was removed by a series of washes (3 × 10 minutes) with dimethyl sulfoxide (DMSO; Sigma-Aldrich, Sydney, Australia) followed by three 10-minute washes with phosphate buffered saline (PBS). For cross-sections, distal colon tissues were pinned and fixed as previously described without stretching, then covered by 50:50 optimum cutting temperature (OCT) compound (Tissue Tek, CA, USA) and frozen in liquid nitrogen–cooled isopentane and OCT and stored at −80°C until cryo-sectioned (20 µm) onto glass slides. For wholemount longitudinal muscle with attached myenteric plexus (LMMP) preparations, distal colon segments were stretched to maximum capacity without tearing, fixed, and washed as previously described. To expose the myenteric plexus, the mucosa, submucosa, and circular muscle layers were removed before immunohistochemical labeling.

**Immunohistochemistry and Histology**

Immunohistochemistry was performed as previously described. Cross-sections and wholemount LMMP preparations were incubated for 1 hour at room temperature in 10% normalized donkey serum (Merck Millipore, Australia). Preparations were then washed (2 × 5 mins) with PBS and incubated with primary antisera (Table 1) overnight at room temperature in an enclosed moist environment. Cross-sections and LMMP preparations were washed with 1x PBS (3 × 10 minute) and incubated with fluorophore-conjugated secondary antisera Alexa Fluor 488, 594, or 647 of the respective antihost species.
(1:200; Jackson Immunoresearch, West Grove, PA, USA) for 2 hours at room temperature. All specimens were stained with 4', 6'-diamindino-2-phenylindole dihydrochloride (DAPI) to label cell nuclei. Tissues were given 3 × 10 minutes final washes in PBS, mounted on glass slides, and cover slipped with fluorescent mounting medium (DAKO, Australia).

Tissues for histology were cryo-sectioned at 10 μm, cleared and rehydrated in graded ethanol concentration. For standard hematoxylin and eosin staining (H&E), sections were immersed in histolene (3 × 4 minutes), 100% ethanol (2 minutes), 95% ethanol (2 minutes), 70% ethanol (2 minutes), rinsed in tap water (30 seconds), then in hematoxylin (Sigma-Aldrich; 1 minute), rinsed in tap water, immersed in Scott’s tap water (1 minute) and eosin (Sigma-Aldrich; 5 minutes), rinsed in tap water, immersed in 100% ethanol (2 × 1 minute) and histolene (4 minutes), and finally mounted on glass slides with DPX mounting media. A histological grading system was used to evaluate gross morphological damage from the following parameters: aberrant crypt architecture (score range, 0–3), changes to crypt length (0–3), crypt abscesses (0–3), leukocyte infiltration (0–3), epithelial damage (0–3), and ulceration (0–3); there was an average of 3 areas of 500 μm² per section. Slides were imaged using an Olympus BX53 microscope (Olympus Imaging, Sydney, Australia). All slides were coded, and analysis was performed blindly.

**Imaging and Quantitative Analysis**

Triple-labeled specimens were visualized and imaged via confocal microscopy (Nikon Eclipse Ti multichannel confocal laser scanning system, Nikon, Japan) using combinations of FITC, Alexa 594, and Alexa 647 filters (495 nm, 559 nm, or 640.4 nm excitation wavelength respectively). Images (1062 × 1062 pixels) were obtained with 20x (dry) or 40x and 60x (oil immersion) lenses. Immunoreactivity for CD45, β-Tubulin, APE1/Ref-1 was analyzed in cross-sections and quantified as a percentage of the area with specific fluorescence relative to the total 2 mm² area of colonic mucosa. Images of 3 colon sections from each tissue sample were captured with a 20x objective to quantify the average area of fluorescence. Immunoreactivity for glial fibrillary acidic protein (GFAP), MitoSOX, and APE1/Ref-1 in LMMP preparations was analyzed in 5 randomly chosen myenteric ganglia. Fluorescence was measured as a percentage relative to the ganglion area, using ImageJ software (NIH, Bethesda, MD, USA). All images for CD45, β-Tubulin, APE1/Ref-1, GFAP, and MitoSOX were acquired with equal acquisition and exposure time conditions, calibrated to standard minimum baseline fluorescence, and converted to binary for analysis of the number of fluorescent pixels per image. Data were normalized and presented as percentage due to the variability in different ganglia and colon sizes between groups. The number of myenteric neurons were counted within 10 randomly selected ganglia (expressed as an average number of neurons per ganglion) and within 4 randomly chosen images per preparation at 20x magnification (total area 1 mm²; expressed as number of neurons per area). The number of neurons with translocation of high mobility group box 1 (HMGB1) from the nuclei to the cytoplasm was quantified with the aid of the nuclei marker DAPI. Longitudinal muscle with attached myenteric plexus preparations were colabeled with MAP2 and 8-OHdG to identify oxidative stress–induced DNA damage within myenteric neurons. The number of myenteric neurons colocalized with 8-OHdG was quantified as a proportion of the total number of neurons within an average of 10 myenteric ganglia. Neurons were counted using the Cell Counter plug-in in ImageJ software. All slides were coded and images were analyzed blindly.

**TABLE 1. Primary Antisera Utilized for Immunohistochemistry**

<table>
<thead>
<tr>
<th>Primary Antisera</th>
<th>Target</th>
<th>Host Species</th>
<th>Titration</th>
<th>Specimen</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-CD45 (ab10558)</td>
<td>Leukocyte Infiltration</td>
<td>Mouse</td>
<td>1:500</td>
<td>Cross-sections</td>
<td>Abcam</td>
</tr>
<tr>
<td>Anti-β-tubulin III (ab18207)</td>
<td>Nerve fibers</td>
<td>Rabbit</td>
<td>1:1000</td>
<td>Cross-sections</td>
<td>Abcam</td>
</tr>
<tr>
<td>Anti-MAP2 (ab5392)</td>
<td>Neurons</td>
<td>Chicken</td>
<td>1:5000</td>
<td>LMMP</td>
<td>Abcam</td>
</tr>
<tr>
<td>Anti-GFAP (ab53554)</td>
<td>Glial Cells</td>
<td>Goat</td>
<td>1:500</td>
<td>LMMP</td>
<td>Abcam</td>
</tr>
<tr>
<td>Anti-APE1/Ref-1</td>
<td>APE1 protein</td>
<td>Mouse</td>
<td>1:1000</td>
<td>Cross-sections</td>
<td>Produced by Mark Kelley’s lab</td>
</tr>
<tr>
<td>Anti-HMGB1 (ab227168)</td>
<td>Damage-associated</td>
<td>Mouse</td>
<td>1:500</td>
<td>LMMP</td>
<td>Abcam</td>
</tr>
<tr>
<td>Anti-8-OHdG (ab48508)</td>
<td>DNA Damage</td>
<td>Mouse</td>
<td>1:200</td>
<td>LMMP</td>
<td>Abcam</td>
</tr>
</tbody>
</table>
Superoxide Production in the Myenteric Plexus

MitoSOX Red M36008 (Thermo Fisher Scientific, Scoresby, VIC, Australia) was used to identify mitochondrial-derived production of superoxide in the myenteric ganglia. Briefly, freshly excised preparations of the distal colon from C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice were dissected to expose the myenteric plexus. Samples were incubated with 5µM MitoSOX Red M36008 at 37°C for 40 minutes. Tissues were washed with oxygenated Krebs solution and fixed with Zamboni’s fixative for 1 hour followed by PBS washes (3 × 10 minutes). Preparations were mounted on glass slides with DAKO fluorescent mounting medium for imaging. Images were captured as described previously. Images were converted into binary, and fluorescent areas were measured in arbitrary units relative to ganglion area using ImageJ software (NIH).

Statistical Analysis

The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology. Data were assessed using 1-way ANOVA with Tukey post hoc tests for multiple group comparison. Analyses were performed using Graph Pad Prism (Graph Pad Software Inc., San Diego, CA, USA). Data are presented as mean ± standard error of the mean (SEM). Value differences were considered statistically significant at P < 0.05.

RESULTS

APX3330 Treatment Improved Clinical Symptoms in Winnie Mice

C57BL/6 control mice did not display any symptoms of inflammation; the signs of diarrhea, rectal prolapse, and bleeding were absent; all C57BL/6 mice produced firm pellets during the 14-day period. All Winnie mice had chronic diarrhea before start of the treatments. Winnie sham-treated mice had chronic diarrhea throughout the whole treatment period; some mice had rectal prolapse evident as a rectal protrusion with edema and bleeding (Fig. 1A). Winnie APX3330-treated mice that had rectal prolapse at the start of the treatment demonstrated reduced rectal prolapse, edema, and bleeding by day 14 of the treatment regimen (Fig. 1A). Colonos were excised, and their length was measured at day 15 (Fig. 1B). Colonos from Winnie sham-treated mice had shorter lengths (75.7 ± 3.2 mm, P < 0.01, n = 5) than C57BL/6 control mice (90.4 ± 3.8 mm, n = 5) and contained soft fecal masses (Fig. 1B'). The APX3330 treatment did not improve the colon lengths (70.4 ± 1.9 mm, P < 0.05, n = 5); however, the presence of hard fecal pellets was prominent similar to C57BL/6 control mice (Fig. 1B-B'). Fecal water content was used as a measure of diarrhea. Fresh fecal pellets were collected on day 14 to assess water content. Winnie sham-treated mice had higher level of fecal water content (83.4 ± 2.7%, P < 0.0001, n = 7) than C57BL/6 control mice (57.3 ± 0.6%, n = 7; Fig. 1C). Conversely, feces from Winnie APX3330-treated mice had lower fecal water retention (73.2 ± 2.1%, P < 0.01, n = 7) than Winnie sham-treated mice but higher levels than C57BL/6 control mice (P < 0.0001; Fig. 1C). Haematoxylin and eosin staining was performed in colon cross-sections to evaluate gross morphological alterations using parameters described in Methods (Fig. 1D). Winnie sham-treated mice attained a higher histological score (8.9 ± 1.4, P < 0.0001, n = 5) compared with C57BL/6 control mice (0.5 ± 0.2, n = 5; Fig. 1D'). The APX3330 treatment reduced histological score in Winnie mice (8.9 ± 1.4, P < 0.001, n = 5). Body weights of C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice were measured over the 14-day period (Fig. 1E). Winnie sham-treated mice showed progressively decreasing body weight which was significantly different from day 6 until day 14 compared with C57BL/6 control mice (Fig. 1E). Winnie APX3330-treated mice grew slowly but not equally well as control C57BL/6 mice and weighed significantly more (99.8 ± 1.0%, n = 8) than Winnie sham-treated mice at day 14 (93.3 ± 1.8%, P < 0.05, n = 10; Fig. 1E).

APX3330 Treatment Reduced Inflammation in the Colon

A pan-leukocyte marker anti-CD45 antibody was used in colon cross-sections to investigate whether APX3330 treatment reduced immune cell infiltration in the Winnie mice colons (Fig. 2A). The density of CD45-IR cells quantified as a percentage of the CD45-IR area relative to the total 2 mm² area of colonic mucosa was significantly higher in Winnie sham-treated mice (24.9 ± 1.8%, n = 5) than in C57BL/6 control (13.6 ± 0.6%, P < 0.01, n = 5) and Winnie APX3330-treated (12.0 ± 1.3%, P < 0.01, n = 5) mice (Fig. 2B). Severity of intestinal inflammation was assessed by the presence of rectal prolapse and Lipocalin-2 (Lcn-2) levels in the feces. Lipocalin-2, also known as neutrophil gelatinase-associated lipocalin, is a noninvasive, highly sensitive and specific biomarker for intestinal inflammation. At day 14, Winnie sham-treated mice displayed a higher fecal Lcn-2 level (46 ± 2.4 pg/mL, n = 5) than C57BL/6 control mice (28 ± 2.4 pg/mL, P < 0.001, n = 5). Treatment with APX3330 decreased fecal Lcn-2 levels (39 ± 1.8 pg/mL, P < 0.01, n = 5), although these were still greater than in C57BL/6 controls (Fig. 2C).

APX3330 Treatment Improved GI Transit in Winnie Mice

The efficacy of APX3330 treatment was assessed on parameters of GI transit and colonic motility. Radiographic images captured movement of the contrast agent barium sulfate from the stomach to the rectum in C57BL/6 control (Fig. 3A), Winnie sham-treated (Fig. 3A) and Winnie APX3330-treated (Fig. 3A”) mice. Total transit time in Winnie sham-treated
FIGURE 1. The effects of APX3330 treatment on clinical symptoms in Winnie mice. A, Images of a C57BL/6 control mouse and a Winnie sham-treated mouse with severe intestinal inflammation and rectal prolapse with blood vessel proliferation and edema before and after 14 days of APX3330 treatment. B, B’: Colons from C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice were excised and their length (mm) measured at day 15 (n = 5/group). C, Fecal water content (the difference between the wet and dry weight) was calculated as a percent of the wet weight of fresh fecal pellets measured at day 14 of treatment (n = 7/group). D, D’: Gross morphology of the distal colon was assessed by H&E staining and histological scoring was quantified in distal colon cross-sections from C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice (n = 5/group). E, Body weight loss or gain in C57BL/6 control (n = 10), Winnie sham-treated (n = 10) and Winnie APX3330-treated (n = 8) mice over the 14-day period. Data expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with C57BL/6 control mice; ^P < 0.05, ^^P < 0.01 compared with Winnie sham-treated mice.
Targeting APE1/Ref-1 for the Treatment of Colitis

(232.9 ± 5.7 mins, n = 7) was longer than in C57BL/6 control (174.3 ± 11.1 mins, P < 0.01, n = 7) mice. The APX3330 treatment reduced the total transit time in Winnie mice (163.3 ± 18.9 mins, P < 0.05, n = 7) to a level comparable with C57BL/6 control mice (Fig. 3B). No significant differences between experimental groups were observed in gastro-rectal transit time (GCTT; Fig. 3C), but other parameters of GI transit were compromised in Winnie sham-treated mice and restored in Winnie APX3330-treated mice. Winnie sham-treated mice had a prolonged contrast retention time in the cecum (165.7 ± 9.7
mins, n = 7) compared with C57BL/6 control mice (93.6 ± 12.8 mins, P < 0.01, n = 7). But the cecum retention time in Winnie APX3330-treated (86.4 ± 17.8 mins, P < 0.01 compared with Winnie sham-treated group, n = 7) was similar to that of C57BL/6 control mice (Fig. 3D). In contrast, colonic transit time was shorter in Winnie sham-treated mice (18.6 ± 2.6 mins,
n = 7) than in C57BL/6 control mice (40.8 ± 5.2 mins, P < 0.01, n = 7) but was restored to control levels in Winnie APX3330-treated mice (37.1 ± 5.7 mins, P < 0.05 compared with Winnie sham-treated group, n = 7; Fig. 3E).

The effects of APX3330 treatment on colonic contractile activity was assessed in ex vivo organ bath experiments (Fig. 4). Colonic migrating motor complexes (CMMCs) are identified as contractions initiated from the oral end that propagated toward the anal end for >50% of the colon length. Video recordings were converted into spatiotemporal maps with contractions identified as orange/red lines (Fig. 4A). Overall, the average length of colonic contractions in Winnie sham-treated mice (21.0 ± 2.6%, n = 6) was much shorter than in C57BL/6 control mice (79.9 ± 4.5%, P < 0.0001, n = 6). The APX3330 treatment increased the length of colonic contractions (74.3 ± 1.7%, P < 0.0001, n = 6; Fig. 4B). Lengths of CMMCs in Winnie sham-treated (50.2 ± 7.2%, n = 6) mice were significantly shorter than in C57BL/6 control mice (68.9 ± 3.7%, P < 0.05, n = 6; Fig. 4C). Winnie APX3330-treated mice had lengths of CMMCs (72.7 ± 0.8%, P < 0.05, n = 6) similar to those of C57BL/6 control mice (Fig. 4C). CMMCs were significantly faster in Winnie sham-treated mice (average

![Image](https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izaa161/5866910)
CMMC speed: 3.3 ± 0.5 mm/sec, n = 6) than in C57BL/6 mice (2.0 ± 0.1 mm/sec, P < 0.05, n = 6). After APX3330 treatment, CMMC speed in Winnie mice (1.8 ± 0.3 mm/sec, n = 6) was significantly slower than in Winnie sham-treated mice (P < 0.05) and comparable with the speed of CMCCMs in C57BL/6 mice (Fig. 4D). CMCCMs in Winnie sham-treated mice (4.0 ± 1.0 CMCCMs/10 mins, n = 6) were significantly less frequent than in C57BL/6 mice (8.0 ± 0.5 CMCCMs/10 mins, P < 0.05, n = 6). Treatment with APX3330 tended to increase the frequency of CMCCMs (6.3 ± 1.0 CMCCMs/10 mins, n = 6) compared with Winnie sham-treated mice, but significant difference was not achieved (Fig. 4E).

APX3330 Treatment Alleviated Enteric Neuropathy in Winnie Mice

An antibody specific to neuronal microtubule protein β-tubulin (β|) was used to label nerve fibres in cross-sections of the distal colon from C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice (Fig. 5A). Winnie sham-treated mice had a significantly lower nerve fibre density in the distal colon (6.7 ± 1.2%, P < 0.001, n = 5) than C57BL/6 control mice (14.4 ± 1.2%, n = 5; Fig. 5A, 5B), while APX3330 treatment improved nerve fibre density in the colon (14.5 ± 0.8, P < 0.001, n = 5; Fig. 5A, 5B).

Myenteric neurons were identified with a pan neuronal marker anti-MAP2 antibody in LMMP preparations from C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice (Fig. 5A). Fewer myenteric neurons per ganglion were observed in Winnie sham-treated mice (20 ± 1 neurons, n = 5) than in C57BL/6 control mice (37 ± 4 neurons per ganglion, P < 0.01, n = 5; Fig. 5A, 5C). The APX3330 treatment alleviated the loss of myenteric neurons in Winnie mice (32 ± 3 neurons per ganglion, P < 0.05 compared with Winnie sham-treated group, n = 5; Fig. 5A, 5C). In Winnie sham-treated mice, there were fewer myenteric neurons per unit area (189 ± 17 neurons per mm², n = 5) than in C57BL/6 control mice (348 ± 36 neurons per mm², P < 0.05, n = 5; Fig. 5A, 5D).

The APX3330 treatment alleviated loss of myenteric neurons (320 ± 34 neurons per mm², P < 0.05, n = 5) compared with Winnie sham-treated mice (Fig. 5A, 5D).

Glia cells were identified with an anti-GFAP antibody assessed in the myenteric plexus of the distal colon relative to the ganglion area in LMMP preparations from C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (Fig. 5A). Winnie sham-treated mice had a significant decrease in glial cell density (15.6 ± 0.6%, n = 5) compared with C57BL/6 control mice (26.5 ± 0.9%, P < 0.01, n = 5; Fig. 5A, 5E). The APX3330 treatment of Winnie mice improved GFAP density (22.0 ± 0.8%, P < 0.01, n = 5) when compared with Winnie sham-treated mice (Fig. 5A, 5E).

APX3330 Treatment Reduced Oxidative Stress and Associated DNA Damage

The fluorescent mitochondrial superoxide marker MitoSOX Red was used to evaluate superoxide production in distal colon myenteric ganglia from C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (Fig. 6A). High levels of MitoSOX fluorescence were evident in the myenteric plexus of Winnie sham-treated mice (30.9 ± 2.7%, P < 0.05, n = 5) when compared with C57BL/6 control mice (16.4 ± 0.4%, n = 5; Fig. 6A, 6B). Increased superoxide production in the myenteric plexus was alleviated in the colons from Winnie APX3330-treated mice (13.8 ± 2.3%, P < 0.01, n = 5; Fig. 6A, 6B).

Translocation of HMGB1 protein from nuclei to cytoplasm identifies its conversion to a damage-associated molecular pattern (DAMP) that is released by dying cells to stimulate an immune response. The HMGB1 translocation from neuronal nuclei to cytoplasm was analyzed within LMMP preparations from C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (Fig. 6A). In Winnie sham-treated mice, many more cells exhibited HMGB1 translocation into the cytosol (17 ± 3 neurons per ganglion, P < 0.01, n = 5) than in C57BL/6 control mice (0 ± 0 neuron per ganglion, n = 5; Fig. 6A, 6C). The APX3330 treatment attenuated cytoplasmic translocation of HMGB1 in the myenteric ganglia (1 ± 0 neuron per ganglion, P < 0.05, n = 5) compared with Winnie sham-treated mice (Fig. 6A, 6C).

The APE1/Ref-1 expression was determined by immunofluorescence within the myenteric plexus in the colon cross-sections and LMMP preparations from C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (Fig. 7A). A significant increase in APE1/Ref-1 intensity was observed in the colon cross-sections from Winnie sham-treated mice (32.2 ± 3.3%, P < 0.0001, n = 5) compared with C57BL/6 control mice (11.7 ± 0.9%, n = 5; Fig. 7A, 7B). The APX3330 treatment reduced this overexpression of APE1/Ref-1 in colon cross-sections (13.8 ± 1.3%, P < 0.001, n = 5) compared with Winnie sham-treated mice (Fig. 7A, 7B). The level of APE1/Ref-1 immunoreactivity was increased within the myenteric ganglia of Winnie sham-treated mice (17.4 ± 1.1%, P < 0.05, n = 5) compared with C57BL/6 control mice (11.8 ± 1.5%, n = 5; Fig. 7A, 7C). In contrast, immunoreactivity in the myenteric ganglia from Winnie APX3330-treated mice (6.2 ± 1.1%, P < 0.001 compared with Winnie sham-treated group, n = 5) was similar to C57BL/6 controls (Fig. 7A, 7C).

Myenteric neurons were co-immunolabeled with a pan neuronal marker, MAP2, and an oxidative DNA damage marker, 8-OHdG (Fig. 8A). Overall, 8-OHdG immunofluorescence density was significantly greater in Winnie sham-treated mice (17.6 ± 1.8%, P < 0.01, n = 5) than in C57BL/6 control mice (4.6 ± 1.1%, n = 5; Fig. 8A, 8B). This immunoreactivity subsided in Winnie APX3330-treated mice (4.6 ± 1.1%, P < 0.001 compared with Winnie sham-treated mice, n = 5; Fig. 8A, 8B).
Targeting APE1/Ref-1 for the Treatment of Colitis

FIGURE 5. THE APX3330 treatment promoted myenteric neuronal survival and ameliorated nerve fiber and glial cell density in the myenteric plexus in Winnie mice. A, Neuronal microtubule proteins were labeled by immunofluorescence using β-tubulin (III; purple) antibody to identify nerve fibers innervating the colon in cross-sections (scale bar = 100 µm, 20x magnification). Anti-MAP2-IR antibody staining (blue) for myenteric neurons in LMMP preparations (scale bar = 50 µm, x40 magnification). Glial cells were labeled with an anti-GFAP antibody (orange) in the myenteric plexus of the colon from C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (scale bar = 50 µm, 40x magnification). B, Density of β-tubulin (III)-IR nerve fibers normalized to colon thickness in C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (n = 5/group). C, Quantitative analysis of myenteric neurons per ganglion C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (n = 5/group). D, Myenteric neurons were quantified per area in LMMP preparations of C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (n = 5/group). E, Density of GFAP-IR glial cells per ganglia in C57BL/6 control, Winnie sham-treated, and Winnie APX3330-treated mice (n = 5/group). Data expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, compared with C57BL/6 control mice; ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 compared with Winnie sham-treated mice.
mice (3.8 ± 1.7%, \( P < 0.01 \), n = 5) to levels comparable with C57BL/6 control mice (Fig. 8A, 8B). These results were consistent with the number of myenteric neurons colocalized with 8-OHdG, which was significantly larger in Winnie sham-treated mice (26 ± 8.0%, \( P < 0.01 \), n = 5) than in C57BL/6 control mice (1.2 ± 1.0%, n = 5; Fig. 8A, 8C) or in Winnie APX3330-treated mice (1.9 ± 0.8%, \( P < 0.01 \) compared with Winnie sham-treated group, n = 5; Fig. 8A, 8C).

**DISCUSSION**

This is the first study to investigate the effects of APX3330, a small molecule inhibitor of APE1/Ref-1 redox signaling, in a clinically relevant animal model of IBD. Our study provides novel findings on the presence of APE1/Ref-1 in enteric neurons, increased level of APE1/Ref-1 in both the mucosa and myenteric ganglia, and significant increase in mitochondrial reactive oxygen species (ROS) production, leading to oxidative DNA damage and translocation of HMGB1 in the colons from Winnie mice. Targeting this pathway with APX3330ameliorated enteric neuropathy and colonic dysmotility and altered GI transit while providing anti-inflammatory and antioxidant effects in the Winnie murine model of spontaneous chronic colitis. These results demonstrate that APX3330 had prominent therapeutic effects in a preclinical animal model of IBD.

The current treatments for IBD are limited due to inefficacy, intolerance, resistance, side effects, and inability to maintain remission. Front-line treatments tend to involve immunosuppression, which has long-term detrimental effects that lead to diminished quality of life in IBD patients. Several new biological treatments have been introduced into clinic that have helped to reduce use of corticosteroids, but many patients stop responding to the clinically approved drugs, so there is still a large unmet need for IBT treatment.

Oxidative stress is a major contributing factor to tissue injury in IBD patients. Reduced mucosal antioxidant capacity and plasma antioxidants have been shown in patients with active CD and UC. However, free radical antioxidants failed in clinical trials, as treatment with general antioxidants does not affect specific signaling and localized oxidative pathways or reversal of DNA damage within cells and subsequently within subcellular elements of cells. Therefore, new therapeutic strategies to block the major sources of oxidative stress are essential. Our study targeted a key molecule involved in oxidative DNA damage/repair mechanisms, APE1/Ref-1, which underpins cellular homeostasis and regulates multiple downstream inflammatory mediators that fuel uncontrolled homeostatic disbalance, causing detrimental effects observed in IBD. APX3330 has the unique ability to suppress inflammation and chemotherapy-induced enhanced redox signaling activity of APE1/Ref-1 while providing neuroprotection in dorsal root ganglion neurons through an increase in oxidative DNA damage repair. A recent phase 1 clinical trial of APX3330 in cancer patients demonstrated no significant toxicities/adverse effects, demonstrated disease stabilization in 6 patients, with 4 on drug for an extended time (252, 337, 357, and 421 days), and predicted pharmacokinetics and target engagement (NCT03375086). Here we tested whether APX3330 alleviates intestinal inflammation, GI dysfunction, and damage to enteric neurons in a preclinical model of spontaneous chronic colitis.

Rectal bleeding, prolapse, chronic diarrhea, and lack of body weight gain are clinical symptoms of chronic colitis in the Winnie mouse model. Treatment with APX3330 improved clinical signs associated with colonic inflammation in this model of chronic colitis. APX3330 attenuated rectal bleeding, improved stool consistency, and prevented loss of body weight in Winnie mice. Gross morphological damage of the colon demonstrated aberrant crypt architecture, crypt elongation, abscesses, epithelial damage and ulceration in Winnie sham-treated mice. Increased colonic crypt length due to epithelial hyperplasia is consistently observed in Winnie mice with chronic colitis and in other models of chronic colitis, although in chemically induced models of colitis (trinitrobenzenesulfonic acid, DSS), both crypt elongation and crypt destruction with mucosal erosion have been reported. These parameters of gross morphological damage were alleviated by APX3330 treatment. High levels of colonic leukocyte infiltration and fecal Lcn-2 are reliable markers of inflammation that are prominent in multiple animal models of experimental colitis in Winnie mice. APX3330 alleviated the immune response in the Winnie mice after a 2-week treatment regimen. This was shown by reduced CD45+ leukocyte infiltration throughout the distal colon and reduced levels of fecal Lcn-2 in Winnie APX3330-treated mice. Further studies need to be performed to define APX3330 effects on specific types of immune cells infiltrating the colon and specific inflammatory mediators.

Winnie mice show an increase in total GI transit time due to a substantial delay in the cecum, although accelerated colonic transit is evident, consistent with previous reports in this model. Similarly, constipation in the proximal colon and accelerated distal colonic transit are common in patients with severe UC. Persistent alterations of GI transit in IBD patients and animal models beyond periods of acute inflammation indicate that damage to the intestinal innervation controlling GI functions is involved. Intrinsic and extrinsic innervations are integral to the functions of the GI tract. Significant changes to intestinal transit result from modulation of the sympathetic and parasympathetic innervation of the GI tract observed in both Winnie and chemically induced models of colitis. In addition to changes in GI transit time, there was a notable decrease in the average length of colonic contractions with a reduction in length, increased speed, and lower frequency of CMMCs demonstrating distorted colonic motor activity in Winnie mice compared with controls. The APX3330 treatment successfully restored total GI and colonic transit time in vivo and colonic CMMC lengths to control levels ex vivo. These
Targeting APE1/Ref-1 for the Treatment of Colitis

FIGURE 6. Effects of APX3330 treatment on superoxide production and HMGB1 translocation in the myenteric plexus of Winnie mice. A, LMMP preparations of the distal colon were labeled with Mitochondrial superoxide marker MitoSOX (red) indicative of oxidative stress. Increased MitoSOX immunofluorescence was evident in the myenteric ganglia of Winnie sham-treated (n = 5) compared with C57BL/6 control (n = 5) mice (scale bar = 100 µm, 40x magnification). This was alleviated in Winnie APX3330-treated (n = 5) mice (scale bar = 100 µm) (A') HMGB1 immunoreactivity (green) colocalized with nuclei marker DAPI (blue) in the myenteric plexus. Translocation of nuclear HMGB1 to cytosol (marked with white arrows) was observed in Winnie sham-treated compared with C57BL/6 control mice and was averted in Winnie APX3330-treated mice (n = 5/group; scale bar = 50 µm, 60x magnification). B, MitoSOX fluorescence intensity was assessed relative to ganglion area. C, The number of cells with translocation of HMGB1 from nucleus to cytoplasm was quantified in the myenteric ganglia. Data expressed as mean ± SEM, *P < 0.05, **P < 0.01 compared with C57BL/6 control mice; ^P < 0.05, ^^P < 0.01 compared with Winnie sham-treated mice.
changes correlate with increased colonic transit time observed in in vivo experiments. Although frequency of CMMCcs has not returned to control levels, overall propulsive activities of the colon become more prominent. This positive modulation of the GI motility suggests that APX3330 treatment has direct or indirect effects on intestinal innervation. Though GI transit is influenced by both extrinsic and intrinsic neurons, the ex vivo contractile activity of the isolated colon is driven mainly by enteric neurons within the myenteric ganglia. Accordingly, we focused on the mechanisms underlying these positive effects of APX3330 treatment in the myenteric plexus.

Intestinal inflammation leads to enteric neuropathy, resulting in compromised GI function. The severity of inflammation in the colon has an impact on myenteric neuronal loss in Winnie mice. Loss of myenteric neurons and neuronal fibers occurs in multiple animal models of intestinal inflammation and in IBD patients. In addition, reduced expression of GFAP-positive glial cells within myenteric ganglia is seen in Winnie mice in this study. In contrast, studies of colonic biopsies from IBD patients, animal models of colitis, and in vitro cultures yielded divergent results on the expression of GFAP in inflammatory conditions.
Targeting APE1/Ref-1 for the Treatment of Colitis

reduced immunofluorescence density of GFAP-positive glial cells in our study may be due to either loss of GFAP-positive glial cells, phenotypic changes, or decreased expression of the protein corresponding to a loss of glial reactivity. Other types of glial cells should be considered in future studies of this model. Enteric glial cells regulate intestinal homeostasis.
and protect enteric neurons from oxidative stress–induced death. Loss of GFAP-positive glial cells causes degeneration of enteric neurons and intestinal inflammation. Altered signaling between enteric glia and neurons contributes to colonic dysmotility. However, in inflammatory conditions, activated enteric glial cells mediate neuronal death via activation of purinergic signaling. Purinergic transmission plays an important role in both excitatory and inhibitory neuronal pathways and sensory transduction in the ENS. Purinergic signaling via P2 receptors plays an important role in controlling nuclear maintenance of APE1/Ref-1. Activation of P2 receptors and intracellular ROS production cause APE1/Ref-1 translocation from the nucleus to cytoplasm, which was also observed in our study. The role of purinergic signaling in regulation of APE1/Ref-1 function in various functional types of enteric neurons needs to be further elucidated.

APX3330 treatment alleviated loss of myenteric neurons, improved nerve fiber, and GFAP immunoreactivity in the myenteric ganglia when compared with Winnie sham-treated mice. APX3330 has been proven to be neuroprotective in sensory neurons after insults caused by ionizing radiation, chemotherapy agents, and inflammatory stimuli all producing oxidative DNA damage acted upon by APE1/Ref-1. These studies showed that enhancement of the DNA repair function of APE1/Ref-1—not its redox signaling—underlies neuroprotective effects of APX3330 in sensory neurons. This was demonstrated using both a genetic and small molecule approach with APX3330. Facilitation of the endonuclease activity of APE1/Ref-1 stimulates base excision repair (BER) of oxidative DNA damage in neurons. Our study provides novel findings on the presence of APE1/Ref-1 in enteric neurons and increased level of APE1/Ref-1 in both the mucosa and myenteric ganglia in the colons from Winnie mice. These results are consistent with findings in the colon tissues removed from IBD patients with active inflammation and in the colonic epithelium of an animal model of DSS-induced colitis. Inflammation caused by pathogenic bacteria, ionizing radiation, ROS, and toxic agents transiently increase intracellular APE1/Ref-1 in gastric epithelial cells and sensory neurons. Our results indicate that APX3330 treatment alleviates the APE1/Ref-1 redox activity in Winnie mice after the 2-week treatment regimen. As APX3330 regulates the inflammatory response, loss of enteric neurons, and immunoreactivity of GFAP in our model of IBD, we tested if these effects result from dysregulation of ROS production in the myenteric plexus.

In the GI tract, the main sources of ROS are the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase,
enzymes (NOX and dual oxidase [DUOX]), NOS and the mitochondrial electron transport chain (mETC). Both NOX and DUOX produce ROS not as a by-product but as a primary function. Gastrointestinal tissues express multiple NOX isoforms, including NOX1, NOX2, NOX4, and DUOX2 within different cell types including macrophages, lymphocytes and neutrophils, epithelial cells, fibroblasts, and glandular cells throughout the GI tract.81 A recent study demonstrated that enteric glial cells increase expression of NOX-2 in response to inflammatory stimuli.82 The NOX expression in enteric neurons of the GI tract has not been investigated. It is known that mitochondria can regulate, activate, differentiate, and aid survival of immune cells.83 Deregulation of the mitochondrial electron transport chain, with increased mitochondrial ROS (mtROS) levels, was observed in IBD patients.84 Oxidants produced by GI cells provide an antibacterial defence.85 Uncontrolled and persistent overproduction of ROS due to upregulation of oxidases or altered mitochondrial function and/or inadequate removal of ROS by antioxidant systems causes tissue injury and exacerbates inflammation, eventually leading to other chronic complications such as fibrosis, neoplasia, and extraintestinal symptoms.47, 48 In addition, it has been shown that the production of ROS induces DNA damage leading to neuronal loss.85 In our study, oxidative stress in myenteric neurons and surrounding cells was shown by the increased mitochondrial superoxide production in Winnie mice. Myenteric neurons in Winnie mice exhibit increased mitochondrial superoxide and oxidative stress–induced DNA damage, as seen in multiple studies that describe increase in oxidative DNA damage in the colonic mucosa of IBD patients9, 20, 88 and chemically induced colitis.21 Our results demonstrate that APX3330 reduced oxidative stress via its redox inhibition of APE1/Ref-1 and oxidative DNA damage in chronic colitis. On the other hand, suppressing APE1/Ref-1’s redox activity with APX3330 enhances APE1/Ref-1’s endonuclease repair activity via the BER pathway, which takes place in both the nuclei and mitochondria. The APE1/Ref-1’s endonuclease activity is responsible for repairing DNA damage induced by oxidative stress, alkylating agents, and ionizing radiation.11, 89 Further studies are required to elucidate APE1/Ref-1’s endonuclease repair activity in enteric neurons after APX3330 treatment.

DNA damage can induce translocation of HMGB1 from the nucleus to the cytoplasm.50–52 Significantly higher numbers of cells in the myenteric plexus of Winnie mice displayed translocation of HMGB1 from the nucleus to the cytoplasm, indicating cellular stress. High mobility group box 1 protein has various functions that depend on its location outside or inside the cell. Acetylated cytosolic HMGB1 released from cells into extracellular space acts as a proinflammatory mediator interacting with immune cells and stimulating production of cytokines and chemokines.37, 93 leading to neuroinflammation, hyperexcitability, and neuronal death.84, 85 APE1/Ref-1 regulates the release of cytosolic HMGB1 and the inflammatory signaling to extracellular HMGB1.96 After APX3330 treatment, HMGB1 was retained in the nuclei of myenteric neurons, thereby reducing release of HMGB1 and presumably increasing survival of colonic myenteric neurons in Winnie mice. This is consistent with findings that nuclear HMGB1 directly interacts with and enhances the endonuclease activity of APE1/Ref-1,97 acting as a cofactor modulating BER capacity in cells.98

CONCLUSION

This study is the first to provide evidence for therapeutic effects of APX3330 in alleviating inflammatory responses, disease severity, GI dysfunction, and enteric neuropathy. Inhibition of mitochondrial superoxide production, APE1/Ref-1 redox signaling, oxidative DNA damage, and translocation of HMGB1 are some of the mechanisms involved in neuroprotective effects of APX3330 in enteric neurons (Fig. 9). Further studies are needed to elucidate more detailed molecular mechanisms underlying the role of APE1/Ref-1, its redox signaling, and DNA damage/repair functions in enteric neurons, in addition to long-term effects of APX3330 treatment. However, results of the recent clinical trial in oncology patients with advanced solid tumors demonstrated that long-term treatment with APX3330 did not show any safety concerns.51, 52 Thus, specific inhibition of the redox signaling function of the APE1/Ref-1 molecule is a novel strategy that might lead to a possible application of APX3330 for the treatment of IBD with good tolerability.

REFERENCES


Targeting APE1/Ref-1 for the Treatment of Colitis


